AstraZeneca PLC Delivers Promising Financial Outlook
AstraZeneca PLC reports its final results, announcing a second interim dividend of $2.17 per share and projected growth in total revenue and core EPS. The company plans to boost investment in tangible and software assets by a third by 2026, while increasing FY 2025 dividends by 3% per share.
AstraZeneca PLC has unveiled its final results, revealing a second interim dividend of $2.17 per share. The pharmaceutical giant anticipates a mid-to-high single-digit increase in total revenue for the fiscal year.
The company projects a low double-digit growth in core earnings per share for the year. Additionally, it has announced a 3% increase in its total declared dividend for the fiscal year 2025, totaling $3.20 per share.
Looking ahead to 2026, AstraZeneca plans significant investments, expecting to increase expenditure on tangible and software-related intangible assets by about a third.
Advertisement
ALSO READ
-
AstraZeneca Eyes Steady Profit Growth Amid Geopolitical Challenges
-
AstraZeneca Expands Cancer Treatment Options in India with Durvalumab
-
AstraZeneca Bets on Cancer Drugs for Steady 2026 Growth
-
AstraZeneca's Ambitious Growth Projections: A Cancer Treatment-Fueled Expansion
-
AstraZeneca Eyes Growth with Oncology and Emerging Markets
Google News